Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 32 | 2023 | 1204 | 3.380 |
Why?
|
| Heart-Assist Devices | 30 | 2023 | 731 | 3.230 |
Why?
|
| Pulmonary Wedge Pressure | 10 | 2021 | 108 | 1.430 |
Why?
|
| Hemodynamics | 14 | 2023 | 710 | 1.410 |
Why?
|
| Heart Transplantation | 7 | 2023 | 705 | 0.920 |
Why?
|
| Ventricular Function, Left | 9 | 2021 | 592 | 0.860 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 376 | 0.740 |
Why?
|
| Aortic Valve Insufficiency | 4 | 2023 | 130 | 0.710 |
Why?
|
| Palliative Care | 1 | 2020 | 257 | 0.660 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 346 | 0.570 |
Why?
|
| Rare Diseases | 1 | 2016 | 59 | 0.560 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2021 | 134 | 0.490 |
Why?
|
| Heart Ventricles | 6 | 2023 | 760 | 0.440 |
Why?
|
| Cardiac Catheterization | 5 | 2020 | 291 | 0.420 |
Why?
|
| Cardiac Output | 4 | 2022 | 156 | 0.420 |
Why?
|
| Middle Aged | 31 | 2022 | 25028 | 0.360 |
Why?
|
| Echocardiography, Doppler | 3 | 2019 | 187 | 0.360 |
Why?
|
| Tricuspid Valve | 2 | 2020 | 96 | 0.340 |
Why?
|
| Thrombosis | 3 | 2020 | 296 | 0.340 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 51 | 0.330 |
Why?
|
| Retrospective Studies | 18 | 2023 | 8489 | 0.330 |
Why?
|
| Thromboembolism | 2 | 2019 | 119 | 0.330 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2020 | 229 | 0.330 |
Why?
|
| Humans | 43 | 2023 | 86643 | 0.320 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 125 | 0.320 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 111 | 0.320 |
Why?
|
| Pacemaker, Artificial | 2 | 2020 | 87 | 0.320 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2020 | 166 | 0.320 |
Why?
|
| Device Removal | 2 | 2019 | 161 | 0.300 |
Why?
|
| Male | 31 | 2022 | 40965 | 0.280 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 95 | 0.270 |
Why?
|
| Female | 30 | 2022 | 44532 | 0.260 |
Why?
|
| Aged | 19 | 2022 | 18415 | 0.250 |
Why?
|
| Echocardiography | 5 | 2020 | 911 | 0.250 |
Why?
|
| Ventricular Function, Right | 3 | 2020 | 142 | 0.240 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2022 | 78 | 0.230 |
Why?
|
| Central Venous Pressure | 2 | 2020 | 26 | 0.230 |
Why?
|
| Cannula | 2 | 2020 | 47 | 0.220 |
Why?
|
| Arterial Pressure | 2 | 2020 | 38 | 0.220 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 306 | 0.200 |
Why?
|
| Aortic Rupture | 1 | 2022 | 55 | 0.200 |
Why?
|
| Incidence | 4 | 2021 | 1577 | 0.200 |
Why?
|
| Aortic Valve | 2 | 2021 | 222 | 0.200 |
Why?
|
| Complement C4b | 1 | 2021 | 35 | 0.200 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 93 | 0.190 |
Why?
|
| Lactic Acid | 1 | 2021 | 90 | 0.190 |
Why?
|
| Prospective Studies | 8 | 2020 | 4213 | 0.190 |
Why?
|
| Sex Factors | 1 | 2023 | 1054 | 0.190 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 29 | 0.180 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 18 | 0.180 |
Why?
|
| Heart | 2 | 2023 | 539 | 0.180 |
Why?
|
| Aminobutyrates | 1 | 2019 | 13 | 0.180 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 74 | 0.180 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 115 | 0.180 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 26 | 0.180 |
Why?
|
| Electric Impedance | 1 | 2020 | 104 | 0.180 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 72 | 0.180 |
Why?
|
| Vasodilation | 1 | 2019 | 96 | 0.180 |
Why?
|
| Tetrazoles | 1 | 2019 | 50 | 0.170 |
Why?
|
| Stroke Volume | 2 | 2019 | 456 | 0.170 |
Why?
|
| Blood Flow Velocity | 1 | 2019 | 197 | 0.170 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 5 | 0.170 |
Why?
|
| Assisted Circulation | 1 | 2018 | 15 | 0.170 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 104 | 0.170 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 90 | 0.170 |
Why?
|
| Counterpulsation | 1 | 2018 | 21 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2020 | 233 | 0.160 |
Why?
|
| Testosterone | 1 | 2019 | 271 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 165 | 0.160 |
Why?
|
| Treatment Outcome | 8 | 2022 | 7993 | 0.150 |
Why?
|
| Thermodilution | 1 | 2017 | 21 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2018 | 181 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 257 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2019 | 377 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 268 | 0.150 |
Why?
|
| Time Factors | 6 | 2020 | 5210 | 0.140 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 129 | 0.140 |
Why?
|
| Graft Rejection | 2 | 2021 | 1065 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2019 | 329 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 3640 | 0.130 |
Why?
|
| Global Health | 1 | 2016 | 193 | 0.130 |
Why?
|
| Postoperative Complications | 3 | 2022 | 2207 | 0.130 |
Why?
|
| Hospitalization | 1 | 2019 | 849 | 0.120 |
Why?
|
| Stroke | 2 | 2020 | 965 | 0.120 |
Why?
|
| Prognosis | 4 | 2022 | 3679 | 0.110 |
Why?
|
| Quality of Life | 1 | 2020 | 1585 | 0.110 |
Why?
|
| Lung | 1 | 2018 | 1170 | 0.110 |
Why?
|
| Prevalence | 1 | 2016 | 1239 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 806 | 0.100 |
Why?
|
| Physicians | 1 | 2019 | 673 | 0.100 |
Why?
|
| Risk Factors | 5 | 2020 | 5417 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2018 | 2261 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2022 | 2767 | 0.090 |
Why?
|
| Adult | 8 | 2020 | 25648 | 0.090 |
Why?
|
| Exercise Test | 2 | 2021 | 164 | 0.090 |
Why?
|
| Illinois | 2 | 2019 | 462 | 0.080 |
Why?
|
| Anticoagulants | 2 | 2019 | 408 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1673 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1801 | 0.060 |
Why?
|
| Thorax | 1 | 2023 | 75 | 0.060 |
Why?
|
| Propensity Score | 1 | 2022 | 136 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2023 | 175 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 25 | 0.050 |
Why?
|
| Axillary Artery | 1 | 2020 | 10 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2021 | 165 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 316 | 0.050 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 44 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2021 | 239 | 0.050 |
Why?
|
| Hyponatremia | 1 | 2020 | 25 | 0.050 |
Why?
|
| Aorta | 1 | 2021 | 280 | 0.050 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 139 | 0.050 |
Why?
|
| Valsartan | 1 | 2019 | 20 | 0.050 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 23 | 0.050 |
Why?
|
| Hemodynamic Monitoring | 1 | 2019 | 8 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 42 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 68 | 0.040 |
Why?
|
| Materials Testing | 1 | 2019 | 91 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 75 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 48 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 224 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 175 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2021 | 460 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 129 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2019 | 280 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2018 | 119 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2018 | 130 | 0.040 |
Why?
|
| Thyroxine | 1 | 2019 | 344 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2019 | 283 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2019 | 278 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2018 | 194 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2019 | 232 | 0.040 |
Why?
|
| Neutropenia | 1 | 2018 | 215 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2019 | 272 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 1163 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 674 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1753 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 159 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2018 | 751 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 685 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 859 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 943 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1139 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1379 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1805 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1991 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1531 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2501 | 0.020 |
Why?
|
| United States | 1 | 2019 | 6672 | 0.020 |
Why?
|